Nesiritide: A review of its use in acute decompensated heart failure

Drugs

Volumn 63, Issue 1, 2003, Pages 47-70

  Keating, Gillian M ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; BRAIN NATRIURETIC PEPTIDE; CELL SURFACE RECEPTOR; DIURETIC AGENT; DOBUTAMINE; GLYCERYL TRINITRATE; NATRIURETIC PEPTIDE RECEPTOR A; NESIRITIDE; NORADRENALIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ALDOSTERONE BLOOD LEVEL; ANGINA PECTORIS; BOLUS INJECTION; BRADYCARDIA; CELL SURFACE; CONGESTIVE HEART FAILURE; DIURESIS; DRUG ABSORPTION; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEALTH CARE UTILIZATION; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HEMODYNAMICS; HUMAN; HYPOTENSION; INFUSION; INOTROPISM; LUNG CAPILLARY PRESSURE; MORTALITY; NATRIURESIS; NAUSEA; PAIN; PHARMACODYNAMICS; REVIEW; STEADY STATE; SURVIVAL; VASODILATATION;

ACUTE DISEASE; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; INFUSIONS, INTRAVENOUS; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; VASODILATOR AGENTS;

ANGINA;

EID: 0037248412     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363010-00004     Document Type: Review

References (69)

1. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J 1997 Jun; 133 (6): 703-12
2. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001 Sep; 22 (17): 1527-60
3. Sharpe N, Doughty R. Epidemiology of heart failure and ventricular dysfunction. Lancet 1998 Aug 29; 352 Suppl. 1: SI3-7
4. Scios Inc. Natrecor® (nesiritide) for injection [online]. Available from URL: http://www.sciosinc.com [Accessed 2002 Jun 4]
5. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. J Clin Invest 1991 Apr; 87: 1402-12
6. Yasue H, Yoshimura M. Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994 Jul; 90 (1): 195-203
7. Yoshimura M, Yasue H, Okumura K, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993 Feb; 87 (2): 464-9
8. Wei C-M, Kao PC, Lin J-T, et al. Circulating β-atrial natriuretic factor in congestive heart failure in humans. Circulation 1993 Sep; 88 (3): 1016-20
9. Gomes MPV, Hobbs RE. B-type (brain) natriuretic peptide: a new therapeutic agent for the treatment of heart failure. Congest Heart Fail 1998 May/Jun; 4 (3): 15-21
10. Clemens LE, Almirez RG, Baudouin KA, et al. Pharmacokinetics and biological actions of subcutaneously administered human brain natriuretic peptide. J Pharmacol Exp Ther 1998 Oct; 287 (1): 67-71
11. Chen HH, Nordstrom LJ, Redfield MM, et al. Subcutaneous BNP administration in symptomatic human heart failure: a novel therapeutic strategy for congestive heart failure [abstract no. 909-2]. J Am Coll Cardiol 2000 Feb; 35 (2 Suppl. A): 240A
12. Protter AA, Wallace AM, Ferraris VA, et al. Relaxant effect of human brain natriuretic peptide on human artery and vein tissue. Am J Hypertens 1996 May: 9 (5): 432-6
13. Roden RL, Asano K, Wichman S, et al. Inotropic effect of human B-type natriuretic peptide in the failing human heart [abstract no. 008]. J Card Fail 1998; 4 (3 Suppl.): 8
14. Michaels AD, Klein A, Lakshmi MV. et al. Effects of intravenous nesiritide on coronary vasomotor regulation and myocardial oxygen consumption [abstract no. 59]. Heart Failure Society of America 6th Annual Scientific Meeting: 2002 Sep 22-25; Boca Raton (FL)
15. Michaels AD, Klein A, Lakshmi MV, et al. Effects of intravenous nesiritide on coronary vasomotor regulation and myocardial oxygen consumption [poster]. Transcatheter Cardiovascular Therapeutics; 2002 Sep 24-29; Washington (DC)
16. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002 Mar 27; 287 (12): 1531-40
17. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000 Jul 27; 343 (4): 246-53
18. Aronson D, Burger AJ. Intravenous nesiritide (human B-type natriuretic peptide) reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure. Am J Cardiol 2002 Aug 15; 90:435-8
19. Aronson D, Horton DP, Burger AJ. Nesiritide improves heart rate variability in patients with decompensated heart failure [abstract no. 4551]. J Am Coll Cardiol 2002 May 1; 39 (9 Suppl. B): 403B
20. Mills RM, LeJemtel TH, Horton DP, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol 1999 Jul; 34 (1): 155-62
21. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: a double-blind, placebo-controlled, randomized crossover trial. Circulation 1996 Dec 15; 94 (12): 3184-9
22. Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998; 4 (1): 37-44
23. Maisel AS, Cremo R, Gardetto N, et al. The effects of nesiritide on serum levels of B-type natriuretic peptide (BNP) in patients admitted for decompensated congestive heart failure [abstract no. 176]. Heart Failure Society of America 6th Annual Scientific Meeting; 2002 Sep 22-25; Boca Raton (FL)
24. Altschul L, Masciello M, Massaro G. Nesiritide in an outpatient infusion clinic setting - case studies on 17 patients [abstract no. 205]. Heart Failure Society of America 6th Annual Scientific Meeting; 2002 Sep 22-25; Boca Raton (FL)
25. Yoshimura M, Yasue H, Morita E, et al. Hemodynamic, renal and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 1991 Oct; 84 (4): 1581-8
26. Brunner-La Roca HP, Kaye DM, Woods RL, et al. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 2001 Apr; 37 (5): 1221-7
27. Jensen KT, Eiskjær H, Carstens J, et al. Renal effects of brain natriuretic peptide in patients with congestive heart failure. Clin Sci 1999 Jan; 96: 5-15
28. Aronson D, Horton DP, Burger AJ. Effects of nesiritide and dobutamine on heart rate variability in patients with decompensated heart failure [poster]. 51st Annual Scientific Sessions of the American College of Cardiology; 2002 Mar 17-20; Atlanta (GA)
29. Mathur VS, Butler J, Emerman CL, et al. Efficacy of B-type natriuretic peptide (BNP) in patients with renal insufficiency and acute heart failure: results from the VMAC trial [poster]. American Society of Nephrology 35th Annual Meeting and Scientific Exposition; 2002 Nov 1-4; Philadelphia (PA)
30. La Villa G, Fronzaroli C, Lazzeri C, et al. Cardiovascular and renal effects of low dose brain natriuretic peptide infusion in man. J Clin Endocrinol Metab 1994; 78 (5): 1166-71
31. Holmes SJ, Espiner EA, Richards AM, et al. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metah 1993; 76 (1): 91-6
32. Jensen KT, Carstens J, Pedersen EB. Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. Am J Physiol 1998; 274: F63-72
33. Hunt PJ, Espiner EA, Nicholls MG, et al. Differing biological effects of equimolar atrial and brain natriuretic peptide infusions in normal man. J Clin Endocrinol Metab 1996; 81 (11): 3871-6
34. Suga S-I, Nakao K, Hosoda K, et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide and C-type natriuretic peptide. Endocrinology 1992 Jan; 130 (1): 229-39
35. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998 Jul 30; 339 (5): 321-8
36. Cody RJ, Atlas SA, Laragh JH, et al. Atrial natriuretic factor in normal subjects and heart failure patients. J Clin Invest 1986 Nov; 78: 1362-74
37. Saul JP, Arai Y, Berger RD, et al. Assessment of autonomic regulation in chronic congestive heart failure by heart rate spectral analysis. Am J Cardiol 1988 Jun 1; 61: 1292-9
38. Casolo G, Balli E, Taddei T, et al. Decreased spontaneous heart rate variability in congestive heart failure. Am J Cardiol 1989 Nov 15; 64: 1162-7
39. Burger AJ, Horton DP, LeJemtel T, et al. The effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J. In press
40. Burger AJ, Aronson D. Effect of vasoactive therapy on heart rate variability in patients with acutely decompensated congestive heart failure. Am J Cardiol 1999 Aug 15; 84: 476-8
41. Givertz MM, Colucci WS. New targets for heart-failure therapy: endothelin, inflammatory cytokines, and oxidative stress. Lancet 1998; 352 Suppl. 1: SI34-8
42. Hobbs RE, Mills RM. Therapeutic potential nesiritide (recombinant b-type natriuretic peptide) in the treatment of heart failure. Expert Opin Invest Drug 1999; 8 (7): 1063-72
43. Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J 1993; 291: 83-8
44. Norman JA, Little D, Bolgar M, et al. Degradation of brain natriuretic peptide by neutral endopeptidase: species specific sites of proteolysis determined by mass spectrometry. Biochem Biophys Res Commun 1991 Feb 28; 175 (1): 22-30
45. Almirez R, Protter AA. Clearance of human brain natriuretic peptide in rabbits; effect of the kidney, the natriuretic peptide clearance receptor, and peptidase activity. J Pharmacol Exp Ther 1999 May; 289 (2): 976-80
46. Young JB, VMAC Study Group. Sustained symptom improvement with nesiritide (B-type natriuretic peptide) compared to IV nitroglycerin in patients with acute decompensated heart failure [abstract no. 2484]. Circulation 2001 Oct 23; 104 (17 Suppl.): 525
47. Abraham WT, on behalf of the VMAC Study Group. Effects of nesiritide (B-type natriuretic peptide) in decompensated heart failure patients receiving beta-blockers [abstract no. 2000]. Circulation 2001 Oct 23; 104 (17 Suppl.): 420
48. Abraham WT, on behalf of the VMAC Study Group. Effects of nesiritide (B-type natriuretic peptide) in decompensated heart failure patients receiving beta-blockers [abstract no. 194 and poster]. 5th Annual Scientific Meeting of the Heart Failure Society of America; 2001 Sep 9-12; Washington (DC)
49. Peacock WF, Emerman CL, Smoluk G, et al. A pilot study of the safety and efficacy of nesiritide in the management of acute decompensated congestive heart failure complicated by an acute coronary syndrome [abstract no. 177]. Heart Failure Society of America 6th Annual Scientific Meeting; 2002 Sep 22-25; Boca Raton (FL)
50. Silver MA, Horton DP, Ghali JK, et al. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 2002 Mar 6; 39 (5): 798-803
51. Elkayam U, Silver MA, Burger AJ, et al. The effect of short-term therapy with nesiritide (B-type natriuretic peptide) or dobutamine on longterm survival [abstract no. 169]. J Card Fail 2000 Sep; 6 (3 Suppl.) 2: 45
52. Hunter CB, Hilleman DE, Malesker MA, et al. Cost-effectiveness of nesiritide in acute decompensated heart failure [abstract no. 221]. Heart Failure Society of America 6th Annual Scientific Meeting; 2002 Sep 22-25; Boca Raton (FL)
53. Burger AJ, Elkayam U, Neibaur MT, et al. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am J Cardiol 2001 Jul 1; 88: 35-9
54. Burger AJ, Horton DP, Elkayam U, et al. Comparison of the effects of dobutamine and nesiritide (B-type natriuretic peptide) on cardiac ectopy in acutely decompensated ischemic versus non-ischemic cardiomyopathies [abstract]. J Card Fail 2000 Sep; 6 (Suppl. 2): 49
55. Scios Inc. Data on file.
56. Middlekauff HR, Mark AL. The treatment of heart failure: the role of neurohormonal activation. Intern Med 1998 Feb; 37 (2): 112-22
57. Stanek B. Optimising management of patients with advanced heart failure: the importance of preventing progression. Drugs Aging 2000 Feb; 16 (2): 87-106
58. Mills RM, Hobbs RE. Drug treatment of patients with decompensated heart failure. Am J Cardiovasc Drugs 2001; 1 (2): 119-25
59. Packer M, Lee WH, Kessler PD, et al. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 1987 Sep 24; 317 (13): 799-804
60. Elkayam U, for the VMAC Study Group. Superior hemodynamic effect of nesiritide (B-type natriuretic peptide) compared to high dose nitroglycerin (NTG) in patients with decompensated heart failure [poster]. National Association of Inpatient Physicians 5th Annual Meeting; 2002 Apr 9-10; Philadelphia (PA)
61. Burger AJ, Dennish G, Dinerman J, et al. Nesiritide therapy for decompensated CHF is not proarrhythmic [abstract no. 1049-155]. J Am Coll Cardiol 2000 Feb; 35 (2 Suppl. A): 172a
62. Tisdale JE, Patel R, Webb CR, et al. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. Prog Cardiovasc Dis 1995 Sep/Oct; 38 (2): 167-80
63. Cuffe MS, Califf RM, Adams KF, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002 Mar 27; 287 (12): 1541-7
64. Colucci WS. Nesiritide for the treatment of decompensated heart failure. J Card Fail 2001 Mar; 7 (1): 92-100
65. Hobbs RE, Mills RM, Young JB. An update on nesiritide for treatment of decompensated heart failure. Expert Opin Invest Drug 2001; 10 (5): 935-42
66. Sweitzer NK. Long-term use of nesiritide (B-type natriuretic peptide) in refractory heart failure without tolerance: a case report [poster]. The Cleveland Clinic Heart Failure and Circulatory Support Summit; 2002 Aug 22-25; Cleveland (OH)
67. Golden JS, Fallick CC, Barnett PP, et al. Intermittent out-patient nesiritide infusion is an effective alternative to hospital admission for the treatment of decompensated heart failure [abstract no. 335]. Heart Failure Society of America 6th Annual Scientific Meeting; 2002 Sep 22-25; Boca Raton (FL)
68. Silver MA, Cheng ML, Congdon S, et al. Management of patients with congestive heart failure after hospitalization - Follow Up Serial Infusions Of Nesiritide (FUSION): clinical trial design [abstract no. 187]. Heart Failure Society of America 6th Annual Scientific Meeting; 2002 Sep 22-25; Boca Raton (FL)
69. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Guidelines for the evaluation and management of heart failure. Circulation 1995 Nov 1; 92 (9): 2764-84